Abstract
Candidiasis is a very common malady in the head neck region. This review will concentrate on intraoral, pharyngeal and perioral manifestations and treatment. A history of the origins associated with candidiasis will be introduced. In addition, oral conditions associated with candidiasis will be mentioned and considered. The various forms of oral and maxillofacial candidiasis will be reviewed to include pseudomembranous, acute, chronic, median rhomboid glossitis, perioral dermatitis, and angular cheilitis. At the end of this review the clinician will be better able to diagnose and especially treat candidal overgrowth of the oral facial region. Of particular interest to the clinician are the various treatment modalities with appropriate considerations for side effects.
Similar content being viewed by others
References
Knoke M, Bernhardt H. The first description of an oesophageal candidosis by Bernhard von Langenbeck in 1839. Mycoses. 2006;49(4):283–7.
Andrews EA, Freund W, Lewis CT, Short C. Harpers’ Latin dictionary: a new Latin dictionary founded on the translation of Freund’s Latin-German lexicon. New York: American Book Co.; 1879.
Odds FC. Candida and candidosis. 2nd ed. Philadelphia: Bailliére Tindall; 1988.
Singh A, Verma R, Murari A, Agrawal A. Oral candidiasis: an overview. J Oral Maxillofac Pathol. 2014;18(Suppl 1):81–5.
Kreger-Van Rij NJW, Lodder J, editors. The yeasts: a taxonomic study. Third revised and enlarged edition. ed.: Amsterdam: Elsevier Science Publishers New York, N.Y. Sole distributors for the USA and Canada, Elsevier Science Pub. Co.; 1984.
Barnett JA. Yeasts: characteristics and identification. 3rd ed. Yarrow D, Barnett L, Payne RW, editors: New York: Cambridge University Press; 2000.
Budtz-Jorgensen E, Stenderup A, Grabowski M. An epidemiologic study of yeasts in elderly denture wearers. Commun Dent Oral Epidemiol. 1975;3(3):115–9.
Jacobsen S, Bryhni IL, Gjermo P. Oral candidosis–frequency, treatment and relapse tendency in a group of psychiatric inpatients. Acta Odontol Scand. 1979;37(6):353–61.
Martin MV, Lamb DJ. Frequency of Candida albicans serotypes in patients with denture-induced stomatitis and in normal denture wearers. J Clin Pathol. 1982;35(8):888–91.
Gallagher JC. Antibiotics simplified. 3rd ed. MacDougall C, editor. Burlington, MA: Jones & Bartlett Learning; 2014.
Homei A, Worboys M. Wellcome trust-funded monographs and book chapters. Fungal disease in Britain and the United States 1850–2000: Mycoses and Modernity. Basingstoke: Palgrave Macmillan; 2013.
Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med. 1994;330(4):263–72.
Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39(3):309–17.
Tsui C, Kong EF, Jabra-Rizk MA. Pathogenesis of Candida albicans biofilm. Pathog Dis. 2016;74(4):ftw018.
Luna LG. Manual of histologic staining methods of the Armed Forces Institute of Pathology. 3rd ed. edited by Armed Forces Institute of P. New York: Blakiston Division, McGraw-Hill; 1968.
Moore TC, Smith DE, Kenny GE. Sanitization of dentures by several denture hygiene methods. J Prosthet Dentist. 1984;52(2):158–63.
Antonelli JR, Panno FV, Witko A. Inflammatory papillary hyperplasia: supraperiosteal excision by the blade-loop technique. Gen Dent. 1998;46(4):390–7.
Infante-Cossio P, Martinez-de-Fuentes R, Torres-Carranza E, Gutierrez-Perez JL. Inflammatory papillary hyperplasia of the palate: treatment with carbon dioxide laser, followed by restoration with an implant-supported prosthesis. Br J Oral Maxillofac Surg. 2007;45(8):658–60.
Orenstein NP, Taylor T. A nonsurgical approach to treating aggressive inflammatory papillary hyperplasia: a clinical report. J Prosthet Dentist. 2014;111(4):264–8.
Salonen MA, Raustia AM, Oikarinen KS. Effect of treatment of palatal inflammatory papillary hyperplasia with local and systemic antifungal agents accompanied by renewal of complete dentures. Acta Odontol Scand. 1996;54(2):87–91.
Murray PA, Koletar SL, Mallegol I, Wu J, Moskovitz BL. Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clin Ther. 1997;19(3):471–80.
FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems Online U.S. Department of Health and Human Services: FDA; 2016 [cited 2018 12/15/2018]. Available from: https://www.fda.gov/drugs/drugsafety/ucm362415.htm#tabs-6.
Funding
This article did not receive any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Research Involving Human and Animal Participants
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed Consent
Informed consent was obtained from all individuals whose photographs are used in this article.
Rights and permissions
About this article
Cite this article
Hellstein, J.W., Marek, C.L. Candidiasis: Red and White Manifestations in the Oral Cavity. Head and Neck Pathol 13, 25–32 (2019). https://doi.org/10.1007/s12105-019-01004-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12105-019-01004-6